Unlock the future of NSCLC treatment
DRG Disease Landscape & Forecast
Non-small-cell lung cancer – Landscape & Forecast – Disease Landscape & Forecast (G7) – report offers a comprehensive analysis of the NSCLC market, providing in-depth insights into its evolving dynamics, emerging therapeutic developments and a 10-year sales forecast. Supported by expert perspectives from 38 oncologist interviews, as well as detailed epidemiological and survey data, it delivers the strategic intelligence necessary for informed decision-making in this rapidly advancing landscape.
Request more information
Key trends in non-small-cell lung cancer treatment:
-
Dynamic market landscape: The NSCLC therapy market is highly dynamic with numerous approved therapies but still faces high unmet needs.
-
Leading immune checkpoint inhibitors: Drugs like Keytruda (Merck & Co.) dominate the field, with broad applicability across various stages and settings of NSCLC. Keytruda gained label expansions in the respectable early-stage space in 2023.
-
Innovative biomarker-targeted therapeutics: These therapies are increasingly driving market segmentation, with new entrants like Braftovi + Mektovi and Augtyro in 2023.
-
Promising drug development: With ongoing advancements in biomarker-driven and immune checkpoint inhibitor therapies, along with expected new market entrants will further intensify competition in the NSCLC market.
Preview only – some data has been intentionally blurred for confidentiality. Full data available in the report.
Key questions answered:
-
How will the recent and expected new market entrants shape the treatment landscapes in the various settings and stages (I-IV) of NSCLC?
-
Which therapies will dominate the commercially lucrative first-line metastatic NSCLC setting?
-
What are the most promising pipeline products, and what will be their likely uptake and patient share in NSCLC?
-
What are the NSCLC therapy market’s key drivers and constraints and how will the market evolve over the forecast period?
Preview only – some data has been intentionally blurred for confidentiality. Full data available in the report.
10-year market forecast (2023–2033)
Annualized drug-level sales and patient share projections across the U.S., EU5, and Japan.
Global Epidemiology & Market Segmentation
Diagnosed incidence of NSCLC by country, histology, stage and line of therapy, segmented into drug-treatable populations.
Pipeline Intelligence powered by Cortellis
Real-time updates on current and emerging therapies, including novel drug classes.
Primary research with 38 interviews with thought-leading medical oncologists
Experts perspectives on treatment adoption, unmet needs and future opportunities.
What is Disease Landscape & Forecast?
Disease Landscape & Forecast is a premier market intelligence platform, offering:
-
Comprehensive market data including world-class epidemiology, current and emerging therapy insights, and robust drug forecasts
-
Dynamic updates ensuring continuous enhancements to reflect indication-specific developments throughout the year
-
Real-time pipeline intelligence coming directly from Cortellis, with daily updates and interactive figures for in-depth analysis
Expert insights on non-small-cell lung cancer
Built on expert knowledge and rigorous research
-
38 thought-leading NSCLC specialists across the G7.
-
Comprehensive epidemiological modeling for non-small cell lung cancer subpopulations.
-
Real-time pipeline intelligence tracking the most promising therapies.
